[144] Mirum Pharmaceuticals, Inc. SEC Filing
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. (MIRM) filed a Form 144 reporting the proposed sale of 40,000 common shares acquired by stock option exercise on 08/11/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,480,000 based on the filing and the company has 50,237,647 shares outstanding as shown.
The filing also records a prior sale during the past three months: Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040. The filer certifies they have no undisclosed material adverse information and notes the securities were paid for in cash at acquisition.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider notice for 40,000 shares (~0.08% of outstanding) from an option exercise; transaction size appears modest relative to company equity.
The Form 144 documents a proposed sale of 40,000 common shares acquired on 08/11/2025 via a stock option exercise, to be brokered by Morgan Stanley Smith Barney. The filing lists an aggregate market value of $2,480,000 and total shares outstanding of 50,237,647. From a capital-markets perspective, this represents a small percentage of the company's float, limiting likely market impact. The disclosure of a prior 40,000-share sale on 08/07/2025 for $2,210,040 provides recent pricing context. The form’s attestation about no undisclosed material information is standard.
TL;DR: Routine insider sale notice; compliance with Rule 144 is documented and the filer affirms no undisclosed material information.
The submission is a standard Rule 144 notice disclosing an insider-related sale following a stock option exercise. It names the executing broker and records a recent related sale by Christopher Peetz. The form includes the required attestation regarding material nonpublic information and notes cash payment at acquisition. From a governance standpoint, the filing satisfies disclosure obligations; no governance irregularities are evident in the document itself.